Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
21 May 2015
Header
Header image
News

News

International Clinical Trials Day – a day to celebrate
19 May 2015

May 20th marks international Clinical Trials Day, a time to recognise the contribution of the many thousands of trial participants, researchers, companies, sponsors, journals, registries [...] Read more

From our blog

From our blog

Life, death and data sharing
21 May 2015 by Andrew Powrie-Smith

Today is International Clinical Trials Day. It means a lot to me. Not just because clinical research has been responsible for an increase in life expectancy of nearly a decade since the 1960s, or because, since the 1980s, death rates from HIV have fallen by around 80%, or even because since the 1990s, death rates from cancer have fallen by 20%, but actually because it has had a significant and direct impact on my immediate family.

Read more

From our blog

Guest blog - Lay summaries: The ultimate completion of your clinical trial
21 May 2015 by Marleen Kaatee

Writing a lay summary is so much more than avoiding difficult words and using a logical structure. It can actually be hugely beneficial to your clinical development, now and in the future! So how can you be transparent and simultaneously boost the interest in clinical trial (CT) participation?

Read more

Events calendar

Events Calendar

Countdown - 1 week: EFPIA Annual Meetings 3-5 June 2015
From 03/06/2015 to 05/06/2015 (Luxembourg)

Only 1 week to go - Register Urgently

EFPIA will be holding its 2015 Annual Meetings from 3 to 5 June in Luxembourg. The event provides an unparalleled opportunity to discuss the key issues driving the European pharmaceutical and healthcare agenda as well as network with senior industry and European stakeholders.

PROGRAMME

REGISTRATION

 

Read more

Events Calendar

15 years after the Orphan Medicines Regulation, are rare disease patients getting the innovation and treatments they need?
On 26/05/2015 (Radisson Blue EU Hotel, Rue d’Idalie 35, 1050 Brussels)

Hosted by Françoise Grossetête and Mr Philippe de Backer MEPs

Building on the 15th anniversary since the adoption of the Orphan Medicines Regulation (EC 141/2000), this conference aims to illustrate the therapeutic advances made possible by the EU framework and to discuss current challenges for rare diseases patients, especially as regards access to diagnosis and treatment. A high level panel of speakers from academia, regulators, industry and patient community will discuss and explore best practices and policy options to address such issues at the EU and at the national level. 

You can download the detailed programme from here.

The report of the event can be downloaded here.

Pictures from the event are available here.

Supported by EFPIA and EuropaBio.

Presentations from the event are available here:

Kerstin Westermark: 15 years after the Orphan Medicines Regulation, are rare disease patients getting the innovation and treatments they need?

- Vinciane Pirard: The pioneering role of rare diseases in science

- Kevin Loth: THE VALUE OF MEDICAL INNOVATION Partnering to improve patient access 

Josep Torrent-Farnell: “Bridging” EU pathways for orphan medicines

 

 

Read more

Events Calendar

FT Digital Health Summit Europe
On 10/06/2015 (London)

The Financial Times is delighted to announce the FT Digital Health Summit Europe: Delivering Scalable and Affordable Innovations, taking place on Wednesday 10th June, in London, UK. Digital [...] Read more

Documents

From our blog

Turning the data sharing principles in to practice: GSK's road to clinical trial transparency
21 May 2015 (Publications)

GSK launched its Clinical Study Register website back in 2004 – before clinical trial data transparency was in fashion. The site, which serves as a [...] Read more

From our blog

Turning the data sharing principles in to practice: UCB shows mid-size pharma can be big on transparency
21 May 2015 (Publications)

In most industries, UCB would be considered a big player. The Belgian-born company has a presence in 40 countries and posted global revenues of €3.3 [...] Read more

From our blog

Turning the data sharing principles in to practice: Why is sharing clinical trial data important to Johnson & Johnson?
21 May 2015 (Publications)

Clinical trial data sharing has the potential to advance the science that is the foundation of medical care. We believe that responsible sharing of clinical [...] Read more

From our blog

Clinical Trials Data Sharing webpage
21 May 2015 ()

According to the EMA, around 4,000 trials are authorised each year across the EEA and this phenomenal effort, in partnership with other global research partners [...] Read more

What we are reading

What we are reading

TradeMarks 2015: What makes associations effective?
21 May 2015 (EurActiv)

The TradeMarks survey measures the extend to which Brussels policy leaders believe associations are effective. The survey was conducted by APCO Insight, in collaboration with EurActiv.

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail